Posaconazole therapeutic drug monitoring: a reference laboratory experience. - Wikidata - awgldk - TriplyDB

Posaconazole therapeutic drug monitoring: a reference laboratory experience.

Posaconazole therapeutic drug monitoring: a reference laboratory experience.

http://www.wikidata.org/entity/Q43128336

about

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.Intracellular concentrations of posaconazole in different compartments of peripheral blood.Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational s Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease.Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome.Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations.Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults.Use of posaconazole in the treatment of invasive fungal infections.Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.Reflections on the approach to treatment of a mycologic disaster.Fatal breakthrough infection with Fusarium andiyazi: new multi-resistant aetiological agent cross-reacting with Aspergillus galactomannan enzyme immunoassay.Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.

P2860

Q26771180-AD940D13-0DB5-4CC2-B54B-C67F345D2BB7 Q33764269-D6C34006-C01F-4021-AB59-2E3E1695A332 Q33962775-A6A23A03-EB56-4DA7-8DA7-0BF0BC624EC2 Q34108484-0D4FAFB4-5616-44DC-AE13-0FA2895958C2 Q34288593-7BC2CA8D-D440-4DEC-B6D9-015EB0C08CA7 Q34309527-8FA98B24-1950-464F-9137-715AF03C0088 Q34596750-229A0E11-0403-4E45-83CD-E266E54E13E4 Q35065903-64E808E4-E666-4301-86F7-6900B5A32473 Q35262607-6F82CF85-ECA7-4B66-912D-9EF0C87FB7B1 Q35944724-65C0596E-00F3-46D3-8248-84728D5ACCCB Q36018743-573A76F0-E628-4325-815F-F706FF448822 Q36276966-616043CC-8834-4508-B43D-92D496B3531E Q36364013-1E456C5B-F7EE-4BD4-BA5C-1460AEF2BC63 Q36396203-53B0E70B-980A-48A9-BD39-8C7A7628ACB4 Q37026715-5D400419-222D-41E4-A37C-31A199CEF038 Q37335720-2D49104F-CB7C-4226-9E77-E7FF8A671AA0 Q37450660-E8134E6A-024D-4356-9C01-4BD73F5F0950 Q37810083-173AD1DA-4B05-4A1C-A7C1-F747A5158A2B Q37813420-D3F70566-F5E7-4A4D-A8EA-2D04E74D1514 Q37904672-805BB585-D5AB-4931-9615-D23181956587 Q39364669-C2A35F8D-B5D4-4FDD-8F97-050A1E98D509 Q39767419-6BA12492-F7F0-4EC0-BA75-5B58B5921BCC Q40215030-4CD75A8D-B70A-406B-B85B-68057B679BBD Q40298087-B72124D1-23DD-4AB7-9CD0-75DAD714F4E6 Q41907424-1F1A168A-CB02-4371-8E96-A5A7B178A087 Q41991703-872E0354-15FD-4F72-A20F-00D7FFE22ABE Q48157814-1DBD332C-018F-4656-BF92-0FC38CF1291B Q51617424-FF4D3E92-EE3D-4CEC-9B0B-D36DEF19FEF0

P2860

Posaconazole therapeutic drug monitoring: a reference laboratory experience.

http://www.wikidata.org/entity/Q43128336

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Posaconazole therapeutic drug monitoring: a reference laboratory experience.

@en

Posaconazole therapeutic drug monitoring: a reference laboratory experience.

@nl

type

label

Posaconazole therapeutic drug monitoring: a reference laboratory experience.

@en

Posaconazole therapeutic drug monitoring: a reference laboratory experience.

@nl

prefLabel

Posaconazole therapeutic drug monitoring: a reference laboratory experience.

@en

Posaconazole therapeutic drug monitoring: a reference laboratory experience.

@nl

P1433

Q43128336-E0559E72-0308-48C8-9DAD-80A69CA357DE

P1476

Q43128336-2EA1CF40-9298-4F61-A024-E487A3B1BC80

P2093

Q43128336-468C0AC3-8D61-4374-A655-3DA0B6BBBEFC

Q43128336-87187518-D755-4B73-8D22-92FAAEB527D2

Q43128336-A2943FE2-4098-4F2E-874F-9DACC2FF265F

Q43128336-AEF702D8-8E66-4C62-BA20-7CC92E02B708

Q43128336-B0DB3901-7B7B-4869-B427-FF6F031629EE

Q43128336-F36902D3-DAD3-4266-B94F-DBADAC25BBBD

P2860

Q43128336-06233C71-FDB2-42EA-9436-1466DD897279

Q43128336-06C35ACA-F6F4-4E51-B322-2DA77FF10022

Q43128336-3030EA4D-1AEB-4D09-AE07-DDD9CA4CD8DB

Q43128336-68AF00CE-AEA4-414A-8B73-3575F29A0C97

Q43128336-86DD25FC-CE5E-4CAC-9BF1-B2F664EADCFC

Q43128336-8F133AA8-C6B0-40B7-8AB0-2AC6911FF62A

Q43128336-96DBD5C4-CBB6-40D3-97AC-ECB9D43B28F6

Q43128336-B50DB8D2-C4C5-4C31-97BF-15031F3F00EA

P304

Q43128336-9226A33E-EFA4-47F8-A98F-E2EDF45D2663

P31

Q43128336-C7780449-8E29-4D3D-8E52-A39952CCEFA6

P356

Q43128336-482A6185-2828-4EE9-9083-E1E69F28D89E

P407

Q43128336-838D72ED-3CD3-4E7C-9A53-2F0B3174F892

P433

Q43128336-0F6E352A-0311-46BC-97BC-C944C25805FB

P478

Q43128336-CFAE9888-6DA3-41F0-B089-FE201F64593E

P577

Q43128336-C7EBDECA-BC40-4588-B997-824F5584847B

P5875

Q43128336-2DF7870C-2D36-4CF8-9A7C-C8231C9F1107

P698

Q43128336-2C1F3903-0E82-44F1-A8F3-A1769C89A5CB

P932

Q43128336-8B757A6E-68EC-48CA-9F77-4871C7161F2F

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Posaconazole therapeutic drug monitoring: a reference laboratory experience.

@en

P2093

Gennethel Pennick

http://www.w3.org/2001/XMLSchema#string

George R Thompson

http://www.w3.org/2001/XMLSchema#string

James S Lewis

http://www.w3.org/2001/XMLSchema#string

Michael G Rinaldi

http://www.w3.org/2001/XMLSchema#string

Sheryl A Dorsey

http://www.w3.org/2001/XMLSchema#string

Thomas F Patterson

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.

Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Antifungal therapeutic drug monitoring: established and emerging indications.

Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.

P304

2223-2224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00240-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24174562

http://www.w3.org/2001/XMLSchema#string

P698

19258264

http://www.w3.org/2001/XMLSchema#string

P932

2681542

http://www.w3.org/2001/XMLSchema#string